VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing
Expands rare cannabinoid portfolio with the addition of CBT and CBDV Strengthens IP with publication of a patent application for novel cannabinoid analogs…
15.02.2022 - Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative .